@jordfinance: Biotech stocks could be worth watching heading into 2027. Cellectar Biosciences (NASDAQ: CLRB) reported an 83.6% overall response rate in its Phase 2b trial and is targeting an FDA accelerated approval submission in H1 2027. Clinical success and FDA approval are never guaranteed. Paid promotion on behalf of Cellectar Biosciences. Not financial advice. Do your own research. #CLRB #BiotechStocks #Investing #StockMarket #Biotechnology

jordyfinance

Open In TikTok:

Region: CA

Wednesday 14 October 2026 14:32:50 GMT